Dyslipidemia

Cardiovascular clinical outcome trials require a large number of sites to meet enrollment targets, but patient-per-site ratios were often low.

Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from the AlloStem pilot study in T2D.

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.

Announced by LIB Therapeutics Inc., the agency has set a PDUFA target action date of December 12, 2025.

Use of medications for secondary CVD prevention is low globally, and in most country income-level groups, with no indication of improvement.

SGLT2 inhibitors lower the risk of MACE in older age, despite smaller HbA1c reductions, while GLP-1 RAs were more cardioprotective in younger individuals with T2D.

Elevated HDL-C raised glaucoma risk, particularly for participants aged ≥55 years, contrary to its typical beneficial role in cardiovascular health.

Lipid screening after bulk orders and outreach letters increased significantly at 3 months, but supplemental text messaging had no further impact.

The January 2025 cardiology month in review highlights new NDA acceptances, clearance of the first Lp(a) test in molar units, and national trends in preventive aspirin use.

Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

A study showed that greater total cholesterol and low-density lipoprotein cholesterol were associated with a quicker decline in global cognition.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

Results from the Phase 3 LIBerate-HoFH trial found LDL-C responses generally similar between patients treated with lerodalcibep and evolocumab.

Awarded to Roche, the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay will be the first 510(k) cleared test measuring Lp(a) in nanomoles per liter (nmol/L).

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

Enobosarm led to a statistically significant benefit in the protection of lean mass in patients with overweight or obesity receiving semaglutide.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

GLP-1 RA initiation boosted new thyroid cancer diagnoses, compared with other anti-diabetic drugs, but enhanced early detection may have played a role.

Subcutaneous amycretin achieved up to a 22.0% weight loss over 36 weeks, with a consistent safety profile to other incretin-based therapies.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.

Grade 2 or 3 cardiac uptake showed a 5-fold higher risk of cardiovascular death compared to grade 1 in asymptomatic ATTR cardiac amyloid infiltration.

Self-reported primary prevention aspirin use decreased among adults with both low and high ASCVD risk after the release of evidence-based guidelines.

Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.

Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

Aspirin avoidance remained safe and did not increase thrombosis risk after LVAD implantation in patients with a history of atherosclerotic vascular conditions.